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130Preoperative smoking is associated with early graft
failure after infrainguinal bypass surgery
Shalini Selvarajah, MD, MPH,a James H. Black III, MD,b Mahmoud B. Malas, MD, MHS,c
Ying Wei Lum, MD,b Brandon W. Propper, MD,b and Christopher J. Abularrage, MD,a,b Baltimore, Md
Objective: Smoking has been implicated as the single most important risk factor for the development of peripheral arterial
disease. Whereas previous studies have found poor long-term outcomes in smokers undergoing lower extremity bypass,
there is a lack of consistent reports describing the effects of persistent tobacco abuse on early outcomes after infrainguinal
bypass.
Methods: The American College of Surgeons National Surgical Quality Improvement Program database from 2005 to
2011 was queried for primary infrainguinal bypasses. A bivariate analysis was done to assess preoperative and intra-
operative risk factors for the primary outcome of 30-day graft failure comparing active smokers with nonsmokers, deﬁned
as patients who did not smoke within the 12 months before surgery. Multivariable logistic regression was conducted to
assess the independent association of active smoking with graft failure.
Results: In 6614 (40.0%) active smokers and 9920 (60.0%) nonsmokers, 16,534 infrainguinal bypasses were performed.
Active smokers were more likely to be younger, male, and of nonwhite race and to have a history of chronic obstructive
pulmonary disease (P < .001, all). Nonsmokers were more likely to be functionally dependent and had signiﬁcantly more
comorbidities (ie, hypertension, diabetes, obesity, congestive heart failure, history of previous cardiac surgery or inter-
vention, and dialysis; P < .001, all). The presence of critical limb ischemia was similar in both groups (53.1% of active
smokers vs 53.5% of nonsmokers; P [ .61). More nonsmokers received a tibial-level bypass than did active smokers
(47.8% vs 33.9%; P < .001). There was a trend toward increased early graft failure in active smokers compared with
nonsmokers (5.3% vs 4.7%; P[ .08). With adjustment for other variables, especially bypass level and graft type, there was
an independent association between active smoking and early graft failure (adjusted odds ratio, 1.21; 95% conﬁdence
interval, 1.02-1.43; P [ .03).
Conclusions: Although nonsmokers were signiﬁcantly older, had more comorbidities, and required more distal revascu-
larization, active smokers still had an increased risk for development of early graft failure. These results stress the need for
immediate smoking cessation before lower extremity bypass. Further research is warranted to determine an optimal
period of abstinence among smokers with peripheral arterial disease to reduce their risk for early graft failure. (J Vasc Surg
2014;59:1308-14.)Smoking has been implicated as the single most impor-
tant and preventable risk factor for the development of pe-
ripheral arterial disease (PAD).1-5 Although the prevalence
of cigarette consumption has declined more than 50%
between 1965 and 2011, more than 45 million adults, or
19% of all adults in the United States, continue to smoke
today.6
The age-adjusted prevalence of PAD among U.S.
adults is 12%, affecting approximately 8 to 12 million
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850% to 90% of patients with PAD are smokers at present
or were smokers in the past.1,9,10 Not only are smokers
more likely to develop PAD, they are also more likely to
have progression of disease.1,2,4,11-13
Whereas smoking has long been identiﬁed as a risk fac-
tor for disease development and progression, a growing
body of evidence suggests smoking as a risk factor for
poor surgical outcomes.14-18 It has been associated with
increased risk of perioperative cardiovascular, pulmonary,
and wound healing complications and has been described
repeatedly in the ﬁelds of general, plastic, orthopedic, and
cardiac surgery.14-18
Several studies in the past have attempted to discern
predictors of graft failure after infrainguinal bypass surgery.
Results from a large meta-analysis, including a newer 2011
publication that examined 187 patient records, showed
that continued postoperative smoking predicted the occur-
rence of graft failure at 1 and 5 years after infrainguinal
bypass surgery.10,19,20 Whereas persistent postoperative
smoking has been more deﬁnitively and consistently impli-
cated in the occurrence of long-term graft failure after
infrainguinal bypass, there is a concomitant lack of consistent
evidence describing the effects of persistent preoperative to-
bacco use on early outcomes after infrainguinal bypass sur-
gery.19 Although Lancaster et al21 identiﬁed smoking
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pendent predictor of early graft failure, this association was
not shown after risk adjustment by Singh et al22 in 2008.
The purpose of this study was to evaluate the impact of
preoperative active smoking on the occurrence of 30-day
graft failure after infrainguinal bypass surgery and to iden-
tify factors associated with smoking status that may explain
the disparity in graft failure rates.
METHODS
Data source and inclusion criteria. This study used
prospectively collected data from the private sector Amer-
ican College of Surgeons National Surgical Quality
Improvement Program (ACS-NSQIP) from 2005 to
2011. The database contains selected clinical information
from the preoperative period through 30 days postopera-
tively for major surgical procedures that are systematically
sampled from participating hospitals. Thorough and
updated information describing NSQIP and its sampling
methodology and program implementation have been
published elsewhere.23,24
The study population was identiﬁed by use of Current
Procedural Terminology codes for infrainguinal bypass
recorded in the principal procedure ﬁeld (35556, 35566,
35570, 35571, 35583, 35585, 35587, 35656, 35666, and
35671). We excluded procedures that were associated with
a primary postoperative International Classiﬁcation of Dis-
eases, Ninth Revision diagnosis code ranging from 444.0
to 444.9 indicating an acute thromboembolic event, nonin-
frainguinal lower extremity procedures performed under the
same anesthetic, and procedures that were coded as reoper-
ations or revisions (35700, 35879, 35881, 35883, and
35884). Finally, cases with missing information for age,
sex, race, smoking status, critical limb ischemia (CLI), and
graft failure (n ¼ 1671) were excluded, resulting in a ﬁnal
cohort of 16,534 infrainguinal bypasses. A complete case
analysis was performed after ensuring that population char-
acteristics comparing the ﬁnal cohort with those excluded
because of missing data were comparable to one another.
Data collection. Variables used in this study include
demographic factors such as age, sex, and race. Race was
recategorized into a binary variable, white vs nonwhite.
Nonwhites comprised blacks, Hispanics, Asians and Paciﬁc
Islanders, and Native Americans.
Body mass index was calculated, and patients with a
body mass index of $30 kg/m2 were classiﬁed as obese.
Active smokers were deﬁned by ACS-NSQIP as persons
who had smoked cigarettes anytime within the year leading
up to surgery.
The presence of predeﬁned comorbidities as well as the
need for red blood cell transfusion within 72 hours before
surgery, preoperative wound infection, and functional sta-
tus were among preoperative risk factors that were
explored. In addition, thrombocytosis was deﬁned as a
platelet count above 400  103/mm3. PAD was deﬁned
by primary diagnosis codes of 440.20 to 440.24 and
443.9 or an NSQIP deﬁnition of “peripheral vascular dis-
ease.” Disease presentation and operative details thatwere collected included the presence of CLI (deﬁned as
the presence of ischemic ulceration or tissue loss related
to peripheral vascular disease), bypass target level (popliteal
vs tibial), type of graft used (vein vs prosthetic), emergency
vs elective surgery, American Society of Anesthesiologists
physical status classiﬁcation, primary surgical team, resident
involvement, any type of major surgery performed within
the past 30 days, and operative time.
The main outcome assessed was the occurrence
of bypass graft failure within 30 days after surgery.
ACS-NSQIP deﬁnes graft failure as a “mechanical failure
of an extra-cardiac graft or prosthesis including myocutane-
ous ﬂaps and skin grafts requiring return to the operating
room, interventional radiology, or a balloon angioplasty
within 30 days of the operation.” To ensure that we were
capturing graft failures related to infrainguinal bypass sur-
gery, we excluded patients who had undergone concurrent
or additional noninfrainguinal bypass procedures that
involved the insertion of a prosthesis, ﬂap, or graft at other
sites. The average number of days to occurrence of graft
failure was also described.
Finally, predeﬁned postoperative complications, mortal-
ity, return to the operating room, postoperative length of
stay, and discharge disposition were analyzed. In addition,
a composite variable to deﬁne early postoperative complica-
tions, comprising any wound, cardiac, pulmonary, renal, or
other complications (bleeding, septicemia, and venous
thromboembolism), was created. This included all compli-
cations occurring before the median time to graft failure.
Statistical analysis. Bivariate analysis was conducted
to describe the distribution of demographic characteristics,
preoperative risk factors, and operative details comparing
active smokers with nonsmokers. For categorical variables,
counts and proportions were presented alongside P values
from c2 and Fischer exact tests. For continuous variables,
distribution of the data was evaluated and tested for
normality by histograms and q-q plots. For normally
distributed data, means and standard deviations were pre-
sented and a t-test was computed. Because operative time
and postoperative length of stay had a skewed distribution,
median and interquartile ranges (IQRs) were presented
and a Wilcoxon rank sum test was performed to test for
equality of medians. Counts and proportions for 30-day
graft failure were computed comparing active smokers
with nonsmokers. Adjusted logistic regression models were
developed by use of variables that were found to be asso-
ciated with both current smoking status and graft failure, in
combination with variables identiﬁed in previous studies, to
assess the impact of current smoking status on early graft
failure.20-22 Interaction terms for smoking status and CLI,
level of bypass and type of graft, and alcohol use and CLI
were tested. Variance inﬂation factors and a condition in-
dex were calculated to test for multicollinearity among
variables controlled for in the ﬁnal regression model.
Nonsmokers were used as the reference category in the
regression analysis. The ﬁnal adjusted odds ratio, its cor-
responding 95% conﬁdence interval, and P value were
presented. A P value of <.05 was considered to be
Table I. Demographic and baseline characteristics of the study population, stratiﬁed by smoking status
Variables
Infrainguinal bypass (NSQIP 2005-2011)
Nonsmokers
(n ¼ 9920), No. (%)
Active smokers
(n ¼ 6614), No. (%)
Total
(N ¼ 16,534), No. (%) P
Mean age 6 SD, years 71.7 6 11.2 62.4 6 10.1 68.0 6 11.7 <.001
Male sex 6169 (62.2) 4389 (66.4) 10,558 (63.9) <.001
White 7566 (76.3) 4977 (75.3) 12,543 (75.9) <.001
Obese 2984 (31.3) 1673 (26.1) 4657 (29.2) <.001
Above moderate alcohol consumption 313 (3.2) 597 (9.3) 910 (5.5) <.001
Comorbidities
Diabetes present <.001
Insulin independent 2115 (21.3) 1115 (16.9) 3230 (19.5)
Insulin dependent 2996 (30.2) 1271 (19.2) 4267 (25.8)
Cardiac
Hypertension 8749 (88.2) 5297 (80.1) 14,046 (85.0) <.001
Angina #1 month 199 (2.0) 131 (2.0) 230 (2.0) .91
AMI #6 months 205 (2.1) 117 (1.8) 322 (2.0) .18
CHF 328 (3.3) 112 (1.7) 440 (2.7) <.001
PCS/PCI 4213 (42.5) 1976 (29.9) 6189 (37.4) <.001
Neurologic
TIA 737 (7.4) 428 (6.5) 1165 (7.1) .02
Pulmonary
COPD 978 (9.9) 1124 (17.0) 2102 (12.7) <.001
Pneumonia 31 (0.3) 12 (0.2) 43 (0.3) .11
Renal
Renal failure 161 (1.6) 71 (1.1) 232 (1.4) .003
Dialysis 1005 (10.1) 274 (4.1) 1279 (7.7) <.001
Others
Preoperative wound infection 4253 (42.9) 1980 (29.9) 6233 (37.7) <.001
Thrombocytosis 750 (7.8) 511 (8.0) 1261 (7.9) .64
Sepsis 424 (4.3) 230 (3.5) 654 (4.0) .01
Bleeding disorder 2286 (23.0) 1545 (23.4) 3831 (23.2) .64
PRBC transfusion <72 hours 96 (1.0) 43 (0.7) 139 (0.8) .03
Dependent functional status 1969 (19.9) 741 (11.2) 2710 (16.4) <.001
Any major operation in the last 30 days 668 (7.2) 363 (5.8) 1031 (6.6) .001
AMI, Acute myocardial infarction; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; NSQIP, National Surgical
Quality Improvement Program; PCS/PCI, previous cardiac surgery/percutaneous coronary intervention; PRBC, packed red blood cell; SD, standard devi-
ation; TIA, transient ischemic attack.
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12.0 (College Station, Tex).RESULTS
Demographic and baseline characteristics in each
study group. A total of 16,534 infrainguinal bypass proce-
dures performed in 6614 (40.0%) active smokers and 9920
(60.0%) nonsmokers were identiﬁed between 2005 and
2011. The mean patient age for the overall study popula-
tion was 68.0 6 11.7 years, and 10,558 (63.9%) were
male. The majority of procedures were performed in pa-
tients who were white (n ¼ 12,543; 75.9%; Table I).
Active smokers were signiﬁcantly younger, of nonwhite
race, and less likely to be obese (26.1% vs 31.3%) compared
with nonsmokers. Fewer active smokers had a cardiovascu-
lar comorbidity such as hypertension, diabetes, congestive
heart failure, previous cardiac surgery or percutaneous cor-
onary intervention, and transient ischemic attack compared
with nonsmokers. Active smokers were less likely to have
end-stage renal disease requiring dialysis, preoperative
wound infection, or sepsis; they were less likely to befunctionally dependent and to have any major operation
within 30 days before infrainguinal bypass surgery.
Presentation and operative details. Overall, 53.3%
(n ¼ 8820) of patients who underwent infrainguinal bypass
during the study period had CLI (Table II). Both active
smokers and nonsmokers who underwent infrainguinal
bypass surgery were equally likely to present with CLI
(53.1% vs 53.5%; P ¼ .61). Signiﬁcantly more active
smokers received proximal revascularizations at the popli-
teal level compared with nonsmokers (66.1% vs 52.2%; P <
.001). Correspondingly, more active smokers received
prosthetic grafts compared with nonsmokers (33.6% vs
30.9%; P ¼ .001).
Themajority of procedureswere performedby a vascular
surgeon (95.0% vs 94.7%; P ¼ .06) and under general anes-
thesia (88.7% vs 90.4%; P¼ .01) for both smokers and non-
smokers. Signiﬁcantly more nonsmokers compared with
active smokers were operated on by a surgical team that
included a resident (65.7% vs 63.8%; P¼ .01).Median oper-
ative time among nonsmokers was longer compared with
that among active smokers (212 minutes [IQR, 157-281]
vs 198 minutes [IQR, 146-267]; P < .001).
Table II. Presentation characteristics and operative details of patients undergoing infrainguinal bypass stratiﬁed by
smoking status
Variables
Infrainguinal bypass (NSQIP 2005-2011)
Nonsmokers
(n ¼ 9920), No. (%)
Active smokers
(n ¼ 6614), No. (%)
Total
(N ¼ 16,534), No. (%) P
CLI 5308 (53.5) 3512 (53.1) 8820 (53.3) .61
Level of bypass <.001
Popliteal 5177 (52.2) 4373 (66.1) 9550 (57.8)
Tibial 4743 (47.8) 2241 (33.9) 6984 (42.2)
Type of graft .001
Vein 6856 (69.1) 4393 (66.4) 11,249 (68.0)
Prosthetic 3064 (30.9) 2221 (33.6) 5285 (32.0)
Emergency procedure 454 (4.6) 288 (4.4) 742 (4.5) .50
Surgical specialty .06
Vascular surgery 9426 (95.0) 6265 (94.7) 15,691 (94.9)
General surgery 488 (4.9) 337 (5.1) 825 (5.0)
Other 6 (0.1) 12 (0.2) 18 (0.1)
Anesthesia .01
General 8797 (88.7) 5980 (90.4) 14,777 (89.4)
Epidural 365 (3.7) 197 (3.0) 562 (3.4)
Spinal 561 (5.7) 327 (4.9) 888 (5.4)
MAC 90 (0.9) 58 (0.9) 148 (0.9)
Regional 94 (1.0) 48 (0.7) 142 (0.9)
Other 12 (0.1) 4 (0.1) 16 (0.1)
ASA class
Life-threatening/moribund 2187 (22.1) 1108 (16.8) 3295 (19.9) <.001
Resident involvement 6497 (65.7) 4205 (63.8) 10,702 (64.9) .01
Operative time, minutes, median (IQR) 212 (157-281) 198 (146-267) 206 (152-276) <.001
ASA, American Society of Anesthesiologists; CLI, critical limb ischemia; IQR, interquartile range;MAC, monitored anesthesia care; NSQIP, National Surgical
Quality Improvement Program.
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cantly more nonsmokers than active smokers had cardiac
(3.1% vs 1.4%; P < .001), pulmonary (3.3% vs 2.3%; P <
.001), renal (2.2% vs 1.5%; P ¼ .001), or other complica-
tions (13.4% vs 10.0%; P < .001) within 30 days of surgery
(Table III). There was, however, no difference in wound
complication rates by smoking status (P ¼ .10). Median
postoperative length of stay was signiﬁcantly longer among
nonsmokers compared with active smokers (5 days [IQR,
3-8] vs 4 days [IQR, 3-6]; P < .001). In addition, more
active smokers than nonsmokers were discharged home
from the hospital (81.9% vs 65.3%; P < .001). Compared
with active smokers, nonsmokers were more likely to be
transferred for further acute or subacute care (18.5% vs
9.8%) or chronic care (16.3% vs 8.3%; P < .001).
Impact of smoking status on 30-day graft failure.
Within 30 days of undergoing an infrainguinal bypass, 823
patients (5.0%) developed graft failure. Unadjusted graft
failure rates were fairly similar comparing active smokers
(n ¼ 353; 5.3%) with nonsmokers (n ¼ 470; 4.7%) (P ¼
.08). The median time to graft failure in the entire cohort
was 5 days (IQR, 1-16). There was no difference in time to
graft failure between active smokers and nonsmokers (P ¼
.61; Table III). Stratiﬁed by level of bypass, active smokers
who underwent popliteal-level bypass had a 31% relative
increase in risk for development of early graft failure than
that of nonsmokers and a 24% relative increase after tibial-
level revascularization (P ¼ .02, both).On multivariate regression, the odds of early graft
failure among active smokers was 21% higher than in
nonsmokers (odds ratio, 1.21; 95% conﬁdence interval,
1.02-1.43; P ¼ .03; Table IV). After adjustment, age, fe-
males, nonwhite race, CLI, distal revascularization, pros-
thetic graft use, alcohol consumption, diabetes, previous
cardiac surgery or percutaneous coronary intervention,
emergency surgery, and the presence of other complica-
tions occurring within the ﬁrst 5 days from surgery
remained signiﬁcantly associated with early graft failure.
Interaction terms that were tested for were not found
to be signiﬁcant and hence were not included in the ﬁnal
model. The ﬁnal model had a Hosmer-Lemeshow test sta-
tistic of P > .05. Variance inﬂation factors that were calcu-
lated to test for multicollinearity ranged between 1.5 and
2.5, and the ﬁnal condition index was below 30.
DISCUSSION
TheprevalenceofPADaffectingU.S. adultshas risen sub-
stantially during the past decade, currently affecting up to 12
million Americans.7,8 Cigarette smoking has been implicated
as one of the most important and preventable risk factors in
the development and progression of PAD.1-3,5,25
Infrainguinal bypass surgery is a well-established treat-
ment modality for suitable candidates presenting with
symptomatic PAD.26,27 The current study analyzed
16,534 patients undergoing infrainguinal bypass surgery,
40% of whom were active smokers before surgery. Within
Table III. Distribution of other postoperative
complications after infrainguinal bypass surgery stratiﬁed
by smoking status
Postoperative
complications
Infrainguinal bypass
(NSQIP 2005-2011)
Nonsmokers
(n ¼ 9920),
No. (%)
Active smokers
(n ¼ 6614),
No. (%) P
Graft failure 470 (4.7) 353 (5.3) .08
Time to graft failure, days,
median (IQR)
6 (1-16) 4 (1-16) .61
Any wound complication 1085 (10.9) 778 (11.8) .10
Wound dehiscence 167 (1.7) 116 (1.8) .73
Superﬁcial SSI 712 (7.2) 506 (7.7) .25
Deep SSI 242 (2.4) 180 (2.7) .26
Organ/space SSI 48 (0.5) 37 (0.6) .51
Any cardiac complicationa 309 (3.1) 94 (1.4) <.001
Any pulmonary complicationb 326 (3.3) 152 (2.3) <.001
Any renal complicationc 222 (2.2) 99 (1.5) .001
Any other complicationd 1333 (13.4) 660 (10.0) <.001
Composite variable of
complications occurring
before median time to
graft failuree
1236 (12.5) 596 (9.0) <.001
Return to operating room 178 (1.8) 114 (1.7) .74
Death 296 (3.0) 104 (1.6) <.001
IQR, Interquartile range; NSQIP, National Surgical Quality Improvement
Program; SSI, surgical site infection.
aIncludes cardiac arrest and myocardial infarction.
bIncludes pneumonia, reintubation, and prolonged ventilation.
cIncludes renal insufﬁciency and dialysis.
dIncludes bleeding, septicemia, and venous thromboembolism.
eIncludes any wound, cardiac, pulmonary, renal, or other complication
occurring within the ﬁrst 5 days after infrainguinal bypass surgery.
Table IV. Multivariable logistic regression of 30-day
graft failure comparing active smokers with nonsmokers
after infrainguinal bypass surgery (N ¼ 16,534)
Graft failure
Odds
ratio
95%
Conﬁdence
interval P
Active smoker 1.21 1.02-1.43 .03
Age 0.99 0.98-0.99 .003
Female 1.27 1.09-1.49 .001
Nonwhite race 1.21 1.02-1.43 .02
Heavy alcohol consumption 0.68 0.46-1.00 .05
CLI 1.73 1.48-2.03 <.001
Tibial-level bypass 2.17 1.84-2.56 <.001
Prosthetic graft 1.27 1.07-1.50 .006
Thrombocytosis 1.21 0.95-1.54 .13
Hypertension 0.95 0.77-1.17 .60
Diabetes 0.78 0.66-0.92 .003
Congestive heart failure 1.30 0.87-1.95 .19
PCS/PCI 0.84 0.71-0.99 .04
Dialysis 0.85 0.64-1.13 .30
Any major operation within past
30 days
1.21 0.94-1.57 .15
Preoperative wound infection 1.10 0.93-1.29 .26
Dependent functional status 1.21 1.00-1.47 .05
Emergency surgery 1.58 1.18-2.13 .002
ASA class 3-5 1.09 0.90-1.32 .35
Resident involvement 1.17 0.99-1.37 .07
Complications occurring before
median time to graft failurea
1.43 1.17-1.75 .001
ASA, American Society of Anesthesiologists; CLI, critical limb ischemia;
PCS/PCI, previous cardiac surgery/percutaneous coronary intervention.
aIncludes any wound, cardiac, pulmonary, renal, or other complication
occurring within the ﬁrst 5 days after infrainguinal bypass surgery.
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patients (5.0%). These ﬁndings are consistent with prior
studies reporting 30-day graft failure rates of 4.5% to
7.4% after infrainguinal bypass surgery.10,21,22
Although smoking is a known risk factor for the devel-
opment and progression of PAD as well as for increasing
the risk of graft failure in the long term, there have been
conﬂicting reports on the role of persistent preoperative
smoking in early graft failure.21,22,28 The two studies that
have examined the effect of preoperative smoking on early
graft failure were analyses of NSQIP as well. Lancaster
et al21 analyzed ACS-NSQIP and identiﬁed active smoking
as an independent predictor of early graft failure. Singh
et al22 similarly reported that active smoking was associated
with early graft failure on univariate analysis in the Veterans
Affairs (VA) NSQIP database. After risk adjustment, the as-
sociation between preoperative smoking status and early
graft failure was lost. However, the VA-NSQIP is
composed of 99% males and 53% active smokers. Not
only are females known to be at greater risk for graft failure,
but the analysis of the VA-NSQIP database did not
compare characteristics of active smokers with those of
nonsmokers. Hence, comorbidity patterns, CLI, and
bypass type (as related to smoking status) were not specif-
ically analyzed in that group of VA-NSQIP patients.This analysis showed that patients who had smoked in
the 1 year leading up to surgery had an overall 19%
increased odds of early graft failure after risk adjustment
compared with nonsmokers. Early graft failure, if it occurs,
is likely to be due to technical failure.10 If patient selection,
preparation, and surgical technique are optimized, graft
failure rates should hypothetically be similar regardless of
smoking status. The increased odds of early graft failure
that was observed in this patient population suggests a like-
lihood that tobacco exposure anytime within the year lead-
ing up to surgery confers a differential risk toward the
development of clinically detectable occlusion even within
the ﬁrst 30 days after surgery.
Prior studies have shown that hydrocarbons, carbon
monoxide, and nicotine in cigarette smoke drive athero-
sclerotic plaque formation by injuring the endothelial lin-
ing within arteries, decreasing high-density lipoprotein,
increasing ﬁbrinogen levels, and promoting platelet aggre-
gation and a hypercoagulable state.11,13,26,29,30 In addi-
tion, methionine-oxidation on thrombomodulin can also
lead to a prothrombotic state seen in smokers.31 It is
possible that persistent cigarette smoke exposure preopera-
tively predisposes a patient to graft failure soon after sur-
gery. It is unclear exactly how long cigarette toxins
remain in the circulation. The 1990 Report of the Surgeon
General stated that whereas the circulation generally
JOURNAL OF VASCULAR SURGERY
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of tobacco remain up to 2 years afterward.32
The presence of CLI, distal revascularization, pros-
thetic graft use, emergency surgery, thrombocytosis, renal
insufﬁciency or failure, and dependent functional status
are among modiﬁable factors that have been associated
with increased graft failure rates.10,19-22,33 The assessment
of comorbidities, presenting features, and intraoperative
details did not reveal that active smokers in this patient
population had higher rates of many of these known pre-
dictors of graft failure, except the use of prosthetic grafts.
Inferior long-term outcomes associated with prosthetic
graft use, especially for distal revascularization procedures,
have been well described in the past.27,28,33,34 The current
results argue for cautious use of prosthetic grafts in active
smokers regardless of level of bypass.
Apart from these risk factors, advancing age, female
gender, and minority race have been shown to be at greater
risk for graft failure.10,21,22,35 In this analysis, younger age
was instead associated with a greater risk for early graft fail-
ure. This was supported by the observation that active
smokers undergoing infrainguinal bypass surgery were
signiﬁcantly younger than nonsmokers. The age gap be-
tween nonsmokers and active smokers was approximately
9.3 years and is consistent with earlier studies describing
that smokers tend to be diagnosed with PAD 10 years
earlier than nonsmokers.1,2,4,11,12
In addition, proportionally more active smokers were
nonwhites. Prior studies have shown that patients of black
race and Hispanic ethnicity are more likely to develop graft
failure at 1 year and 5 years after infrainguinal bypass
surgery.35,36
Distal revascularization poses signiﬁcantly more tech-
nical challenges to a vascular surgeon than proximal-level
bypasses do. Patients with diabetes and other cardiovascular
comorbidities have been shown to be more prone to devel-
opment of infrapopliteal atherosclerotic disease, whereas
smokers are more likely to develop atherosclerotic plaques
in larger and more proximal lower limb vessels, especially
the superﬁcial femoral artery.2,26 In this study population,
there were approximately 1.5 times more patients with dia-
betes in the nonsmoking group than in the active smoking
group. This may explain why there were more active
smokers who received a popliteal-level bypass, whereas
signiﬁcantly more nonsmokers received tibial-level bypasses.
However, despite being more likely to receive a proximal
bypass, active smokers still had a greater risk for develop-
ment of early graft failure. Stratiﬁed by bypass target site,
early graft failure continued to occur more frequently in
active smokers than in nonsmokers, but the relative differ-
ence in this risk was greater in patients who received prox-
imal bypasses. In addition, more active smokers received
prosthetic grafts. This could have been related to more
proximal bypass target sites or inadequate autogenous vein.
Although this study population comprised active
smokers who were signiﬁcantly younger and had fewer co-
morbidities, better functional status, and more popliteal-
level bypasses, their odds for early graft failure was 19%higher than in nonsmokers, a disparity thatwas largely driven
by a greater proportion of them receiving proximal-level
bypasses and prosthetic grafts. This study, however, is
limited by its observational nature, which only allows the as-
sociation between persistent preoperative smoking and the
occurrence of early graft failure after infrainguinal bypass
to be described without implying causality. Furthermore,
the ACS-NSQIP database does not contain regional or
facility-based identiﬁers. Clustering effects from regional
variations cannot be accounted for in our analysis. In addi-
tion, apart from reporting a history of CLI, there was no
additional clinical information that enabled the identiﬁca-
tion of the exact location, the length and state of the affected
lower limb vasculature, or the availability or quality of autog-
enous conduit. Active smoking deﬁned in NSQIP did not
include all forms of tobacco use but only cigarette smoking.
In addition, the intensity and duration of smoking are inad-
equately addressed in the database. Information for pack-
years of smoking in the database was missing in 40% of the
study population. Nonsmokers comprised persons who
were never smokers and past smokers. Furthermore, among
past smokers, time point of smoking cessation is not known.
Despite these limitations, the main strength of this
analysis is in the large number of real-world infrainguinal
bypass procedures that was accessible for analysis. This
resulted in a power of 81% to detect a signiﬁcant difference
in the occurrence of early graft failure across smoking sta-
tus. In addition, this is one of the largest analyses specif-
ically examining the impact of persistent preoperative
smoking on the occurrence of early graft failure after
infrainguinal bypass surgery.
CONCLUSIONS
Patients who continue to smoke anytime within the
year leading up to infrainguinal bypass surgery have an
increased risk-adjusted odds for development of early graft
failure. Further research is warranted to determine an
optimal period of smoking abstinence among active
smokers requiring infrainguinal bypass surgery to minimize
their risk for early graft failure. For this, a deeper under-
standing of the role of duration and intensity of smoking
in this patient population is necessary to optimize the suc-
cess of preoperative smoking cessation plans.
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